Article Figures & Data
Additional Files
Data Supplement
- Supplemental Data -
Supplemental Materials and Methods.
Supplemental Table S1. Analytical equipment used in the hADME study (NCT04407091).
Supplemental Table S2. Key inclusion and exclusion criteria for participants in the hADME study (NCT04407091).
Supplemental Table S3. Analytical conditions for metabolite profiling in the hADME study (NCT04407091).
Supplemental Table S4. Summary of control substrates and metabolites used for the in vitro determination of UGT isoform involved in glucuronide metabolite formation.
Supplemental Table S5. Summary of substrates and metabolites used for the RAFs previously determined by Busse et al. (Busse et al., 2020).
Supplemental Table S6. Demographics and baseline characteristics of healthy participants in hADME study (NCT04407091).
Supplemental Table S7. Arithmetic mean (SD) cumulative fraction of 14C dose (%) excreted as total 14C in urine, feces, and total (urine + feces) following a single oral dose of 10 mg of 14C-AZD4831 (as a solution) over 0–336 hours in healthy volunteers.
Supplemental Figure S1. LC-MS/MS chromatograms monitoring the concentrations of AZD4831 (μmol/L) in rat plasma following a single intravenous or oral administration of M7 in Hans Wistar rats.
- Supplemental Data -
